Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Two-period, Placebo Controlled, Forced-titration Proof of Concept Crossover Study to Compare QGC001 With Placebo in Patients With Grade I or II Essential Hypertension

NCT02322450 is registered in ClinicalTrials.gov with Quantum Genomics SA as lead sponsor.

NCT NCT02322450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02322450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Two-period, Placebo Controlled, Forced-titration Proof of Concept Crossover Study to Compare QGC001 With Placebo in Patients With Grade I or II Essential Hypertension
Lead sponsor
Quantum Genomics SA
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2015
Completion date
April 30, 2016
Enrollment
34 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension